Odirab D 30mg/20mg Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and alleviating acid-related discomfort. The synergistic effect of these agents provides both symptomatic relief and addresses the underlying pathophysiology of acid reflux and delayed gastric emptying. Odirab D is typically administered orally once daily before meals, with dosage adjustments based on clinical response and tolerability. It is contraindicated in patients with known hypersensitivity to either component, and caution is advised in those with hepatic impairment or cardiac arrhythmias. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Consultation with a healthcare professional is recommended prior to initiation to ensure appropriate use and monitoring.